GSK, GB00BN7SWP63

GSK stock: Patent ruling supports licensing leverage; shares slip 0.44%

Published on 11/16/2026 at 08:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
A Hague court ruling strengthens GSK's position in licensing talks over RNA vaccine technology. On Xetra, the stock closed at EUR 22.91 on Friday, November 13, 2026.

Key legal and market points

  • A Hague court upheld most of GSK's RNA-delivery patent against Pfizer and BioNTech's Comirnaty vaccine.
  • The injunction is subject to a final decision and a further three-month licensing period.
  • Pfizer and BioNTech face interim damages of EUR 2 million and can appeal.
GSK, GB00BN7SWP63, Illustration mit AI erstellt.

GSK stock traded at 22.81 euros on Lang & Schwarz at 08:11 CET on Monday, November 16, 0.44 percent below the Xetra close of Friday, November 13.

Patent ruling strengthens licensing position

On November 10, the Unified Patent Court's Hague division found that Pfizer and BioNTech's Comirnaty vaccine infringes most of GSK's European patent covering liposomes used to deliver RNA. The court upheld the patent almost in full, with only one claim revoked, according to Juve Patent.

The ruling grants an injunction across most relevant European Patent Convention countries, but enforcement is postponed until the decision becomes final and a three-month licensing window expires. Pfizer and BioNTech must also provide sales information and face interim damages of EUR 2 million. The companies can appeal, limiting the immediate commercial effect while increasing GSK's leverage in licensing discussions.

UK equities can be followed through the FTSE 100.

More news and analyses on GSK stock.

Disclaimer...
en | GB00BN7SWP63 | GSK | boerse | 70519660 | bgmi